Accelr8 Announces New Microarraying Products & Production Relationship

    DENVER, Feb. 14 /PRNewswire-FirstCall/ --
 Accelr8 Technology Corporation (OTC Bulletin Board:   ACLY) announced the
 introduction of high-performance microtiter plates at the Association of
 Biomolecular Resource Facilities Annual Meeting in Denver.  The new products
 join the company's line of high-performance OptArray(TM) microarraying slides.
 The plates and slides both feature the company's proprietary OptiChem(TM)
 activated surface chemistry.
     Accelr8 developed the new products in cooperation with Greiner Bio-One
 GmbH, a German manufacturer of high quality microtiter plates.  Under the
 production agreement, Accelr8 supplies Greiner with OptiChem-coated glass
 plates.  Greiner then bonds the coated glass to their bottomless polystyrene
 microtiter plate and packages the finished product.
     The new products are the first to support high performance microarraying
 applications in the microplate format.  Accelr8's early entry into this
 application space provides an excellent opportunity to capitalize on industry
 experts' belief that plate-based microarraying is about to provide a new level
 of interest in gene and protein arraying.  Accelr8's product launch is
 well-timed, as instrument makers are supporting this industry trend by
 introducing high-volume arraying and plate scanning capabilities.  The new
 plates close a gap in the rollout of plate-based arraying, leveraging the
 large investments in high throughput plate-handling robotic systems owned by
 drug discovery laboratories.
     According to Thomas V. Geimer, Accelr8's CEO and Chairman, "The new
 product line takes us into specialty areas of the established market for
 microtiter plates.  We're one of the first companies to bring high-performance
 microarraying to the plate format.  OptiChem(TM) delivers the same benefits on
 a plate as with our OptArray(TM) glass slides.  For example, in the area of
 drug discovery, we believe that our advanced microplate technology will
 significantly improve data quality and shorten the time to results."  He
 continues, "We're also particularly pleased with our relationship with Greiner
 Bio-One.  They are a leading global supplier of microtiter plates and other
 laboratory products, and they enjoy a reputation for high quality and
 excellent service.  This relationship demonstrates our commitment to work with
 market leaders to establish Accelr8's technology in life sciences markets."
 
     Certain statements in this news release may be "forward-looking
 statements" within the meaning of Section 27A of the Securities Act of 1933,
 as amended, and Section 21E of the Securities Exchange Act of 1934, as
 amended.  Statements regarding future prospects and developments are based
 upon current expectations and involve certain risks and uncertainties that
 could cause actual results and developments to differ materially from the
 forward-looking statement, including those detailed in the company's filings
 with the Securities and Exchange Commission.
 
 

SOURCE  Accelr8 Technology Corporation